Accesso Biotech Corporation is launching the Ecco™ Imaging Cytometer, designed for the cell therapy product development and manufacturing market. Built on the same technology as the VITA™ point-of-care CD4 counting system, developed for AIDS patients in low- and middle-income countries, the Ecco™ Imaging Cytometer enables flow cytometry-like immunophenotyping and absolute cell counting of gated cell populations-without the need for lasers, fluidics, or counting beads. This low-cost, portable, and easy-to-use system is ideal for routine testing in blood centers and QC testing in GMP environments. Its cartridge-based format allows for direct immunophenotyping and cell counting using whole blood samples—without the need for lysing or washing. We welcome inquiries for custom assay development as well as requests for demo testing. For more details, please visit our website: https://www.accessobio.com/cell-research.

Visit Website

Carrigent is a technology developer focusing on the cell and gene therapy industry. We are developing technologies for viral vector production, concentrating on three major problems in the space: production costs, gene-of-interest size limitations, and in vivo targeting. In addition, we provide contract research and pre-clinical process development services for the optimization of viral vectors and vector production systems to provide vectors that are more efficient and effective.
We have made breakthroughs in both the viral backbones and their expression systems, and our newest technology is our non-viral, non-lnp, non-vlp targeted payload delivery system, capable of delivering large sized protein, DNA or RNA directly to the cell type of interest and will be launching in 2025.

Visit Website

Cytotheryx is a platform technology company focused on developing a consistent, high-quality source of primary human hepatocytes, the functional cells of the liver, and the utilization of those cells in the research and therapeutic markets. Our proprietary technology was originally developed at, and is licensed from, the Mayo Clinic in Rochester, MN. The availability of a high-quality source of primary human hepatocytes will open the door to developing curative treatments for liver disease, meeting several critical unmet needs.

Visit Website

Defined Bioscience Inc. is a biotechnology company dedicated to advancing stem cell research and cell-based therapies by providing innovative, high-performance media formulations and reagents. Founded by a team of academic and industry experts, Defined Bioscience specializes in chemically defined, animal-free solutions that support consistent and scalable stem cell culture, differentiation, and organoid development. Our product portfolio includes the HiDef™ series of culture media, Ready-CEPT™, and thermostable growth factors, all designed to enhance the reproducibility and efficiency of stem cell-based assays, biopharmaceutical production, and regenerative medicine applications. By eliminating variability in cell culture conditions, we empower researchers and biopharmaceutical companies to accelerate discovery and translational development. Defined Bioscience operates as both a product supplier and a research partner, collaborating with leading biotech and pharmaceutical companies to optimize stem cell culture systems for drug development and cell therapy manufacturing. With a commitment to scientific excellence, rigorous quality control, and innovative solutions, we aim to enable the next generation of cell-based therapies.

Visit Website

faCellitate is at the forefront of developing innovative biomimetic materials, essential for advancing applications in 3D cell culture, industrial biotechnology, regenerative medicine, and cell therapies. Leveraging a proprietary platform technology, faCellitate creates scalable, chemically defined surface coatings designed to meet the rigorous demands of modern life science research and industrial production. The company's product portfolio features BIOFLOAT™, a top-performing solution for 3D spheroid production, and BIOINSTRUCT, a synthetic matrix tailored for the cultivation of induced pluripotent stem cells (iPSCs). These products are distinguished by their mechanical durability, ease of use, and capacity to support scalable production, enabling researchers and organizations to achieve reproducibility and high-performance results in their workflows. faCellitate’s surfaces are engineered with a focus on precise cellular interactions, providing a defined and controlled environment that mimics natural cellular niches. This approach enhances cell viability, functionality, and differentiation, offering significant advantages for high-throughput screening, tissue engineering, and therapeutic development.

Visit Website

OspreyBio is positioned to be the first end-to-end gene and cell therapy research tools and services company. Our mission is to empower researchers and companies to design, build, and optimize next-generation therapies with unparalleled precision and efficiency. At the core of OspreyBio’s offerings is our flagship Bird of Prey (BoP) platform—the first modular and standardized DNA design and construction system. By leveraging a robust library of pre-made DNA modules, the BoP platform enables faster and more cost-effective vector construction, either in-house or as a service. Unlike other vendors, we tackle even the most complex multigenic vectors. Our library includes therapeutically relevant ORFs, bioRNA, novel promoters (Transcription Units), IRES elements, reporters, and more—each designed for seamless assembly and compatibility to meet the growing demands of modern genetic engineering. In addition to our modular DNA tools, OspreyBio provides comprehensive vector assembly and construction services, supporting a broad range of applications. These include basic research vectors (e.g., reporter and protein/RNA expression) as well as translational research vectors (e.g., disease models and therapeutic constructs).

Visit Website

ReelReactor™ is a cutting-edge continuous micro-batch reactor designed to revolutionize biologics manufacturing. Unlike traditional batch systems, which suffer from poor scalability, inconsistent quality, and high costs due to time-dependent reactions, ReelReactor enables precise, scalable, and cost-effective continuous production. Engineered for cell and gene therapy and other biologics, ReelReactor features functionally closed, sterile single-use consumables and biologically inert wetted materials. Its unique design ensures constant, gentle mixing, preserving product integrity, and it seamlessly integrates into larger workflows, eliminating bottlenecks. By bridging the gap between batch and continuous manufacturing, ReelReactor empowers biopharma companies to accelerate development, reduce manufacturing costs, and improve product consistency. Whether for feasibility studies, small-scale manufacturing, or full-scale production, ReelReactor provides an innovative, flexible platform to meet the evolving needs of modern bioprocessing.

Visit Website

Telos Biotechnology is revolutionizing cell therapy manufacturing with TELOVANCE™, a proprietary telomere-lengthening platform designed to enhance the expansion and efficacy of engineered cell therapies. Telos’ breakthrough technology addresses a critical limitation in CAR T-cell therapy—T-cell senescence and exhaustion, which contribute to poor long-term remission rates. The Challenge: CAR T-cell therapy has transformed cancer treatment, but nearly 50% of adult patients fail to achieve durable responses. One major contributor is immunosenescence, where T-cells progressively lose function due to telomere shortening, limiting their expansion potential and persistence. The Solution: TELOVANCE™ is a recombinant human telomerase holoenzyme that transiently extends telomeres during ex-vivo CAR T-cell manufacturing, increasing replicative lifespan and cytotoxicity without genetic modification. Our in-vitro and in-vivo data demonstrate that TELOVANCE-treated CAR T-cells outperform untreated counterparts in durability and anti-tumor activity. The telomerase enzyme is naturally degraded within 48 hours, ensuring safe and transient telomere elongation. Telos is actively collaborating with leading biotech, pharma and CDMO companies to integrate TELOVANCE™ into next-generation cell therapies. For partnership inquiries, visit TelosBio.com or email info@telosbio.com .

Visit Website

Tolemy Bio is transforming the cell and gene therapy (CGT) industry by creating precision-engineered, custom cell culture media formulations. Using cutting-edge AI and machine learning, Tolemy unlocks new possibilities in cell metabolism optimisation that go beyond the limits of current methods. Our innovative, data-driven media solutions empower CGT manufacturers to accelerate development timelines, improve product quality, and bring life-saving therapies to patients faster than ever before.

Visit Website